VivoSeq
Dermatology

Chronic Hand Eczema

0

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Chronic Hand Eczema is an early-stage landscape with 0 programs across 4 companies. The most active players are LEO Pharma, Incyte, Basilea Pharmaceutica.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

LEO Pharma logo

LEO Pharma

0 programs

PreclinicalIncyte logo

Incyte

0 programs

PreclinicalBasilea Pharmaceutica logo

Basilea Pharmaceutica

0 programs

PreclinicalA

Asana BioSciences

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

12

clinical trials

Completed8 · 67%
Withdrawn2 · 17%
Recruiting1 · 8%
Unknown status1 · 8%

Clinical Trials

Trial Activity

12 trials

Treatment of Chronic Hand Eczema With Oral Roflumilast (HERO)
Recruiting·—·Phase 4·NCT05682859·40 enrolled
Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema
Completed·LEO Pharma logoLEO Pharma·Phase 2·NCT02664805·91 enrolled
A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema
Completed·LEO Pharma logoLEO Pharma·Phase 3·NCT06004050·362 enrolled
Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
Completed·IInnovaderm Research Inc.·Phase 2·NCT06283550·82 enrolled
Alitretinoin in the Treatment of Chronic Hand Eczema
Completed·Basilea Pharmaceutica logoBasilea Pharmaceutica·Phase 3·NCT00519675·150 enrolled
Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema
Completed·LEO Pharma logoLEO Pharma·Phase 1·NCT05486117·15 enrolled
Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema
Completed·LEO Pharma logoLEO Pharma·Phase 2·NCT03683719·258 enrolled
Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema
Completed·AAsana BioSciences·Phase 2·NCT03728504·97 enrolled
Topical Ruxolitinib Evaluation in Chronic Hand Eczema
Completed·Incyte logoIncyte·Phase 2·NCT05906628·186 enrolled
Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1
Withdrawn·Incyte logoIncyte·Phase 3·NCT05219864
Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2
Withdrawn·Incyte logoIncyte·Phase 3·NCT05233410
Dupilumab in Severe Chronic Hand Eczema
Unknown status·UUniversity Medical Center Groningen·Phase 2·NCT04512339·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)